Loading
Life sciences · Journal article
BMC Urology · October 15, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Background Peritoneal and omental metastasis from prostate adenocarcinoma is rare and usually occurs in the setting of widespread disease. Isolated peritoneal involvement without skeletal or nodal disease is uncommon, and the mechanism of spread is not well understood. Case presentation A 64-year-old man presented with lower urinary tract symptoms and was diagnosed with high-risk prostate adenocarcinoma (Gleason 4 + 5=9, WHO Grade Group 5) after transurethral resection of the prostate (TURP); post-operative prostate-specific antigen (PSA) was 7.8 ng/mL, and the pre-operative work-up was not available. Staging with prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) showed locally invasive disease extending into the seminal vesicles and bladder base, without nodal or distant metastasis. He was treated with hormonal therapy and external beam radiotherapy, achieving a PSA nadir of 0.35 ng/mL. Despite a subsequent rise in PSA, a surveillance PSMA PET/CT was negative for recurrence. PSA continued to rise progressively, reaching 59.17 ng/mL, with new lower urinary tract symptoms. Repeat PSMA PET/CT showed ascites and diffuse PSMA-avid omental caking with peritoneal fat stranding, without local recurrence, lymphadenopathy, or osseous metastasis. Image-guided tru-cut biopsy of the omentum confirmed metastatic carcinoma compatible with the known prostatic primary. He was started on docetaxel with continued luteinizing hormone-releasing hormone (LHRH) therapy, abiraterone, and prednisolone, and remains under oncological surveillance. Conclusion Peritoneal and omental recurrence can occur after TURP-diagnosed prostate cancer without involvement of the usual sites of spread, and a TURP-related iatrogenic contribution cannot be excluded. A negative PSMA PET/CT does not exclude progression; in selected patients with a marked, sustained PSA rise and new symptoms, repeat imaging may be considered when it is likely to alter management, and histopathological confirmation is required when an atypical metastatic site is suspected.